NICE recommendations for drug coverage shown to have little impact

05/26/2004 | Financial Times (free content)

Pharmaceutical industry and related studies indicate the U.K.'s National Institute for Clinical Excellence, which recommends to the National Health Service which drugs to cover, has little impact on the introduction of new treatments. If the NICE recommendations had been adopted, according to studies by Roche, NICE and the Association of British Pharmaceutical Industry, they would have added millions to NHS drug coverage costs.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC